IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Lowered by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 16,474 shares of the company’s stock after selling 1,963 shares during the quarter. Commonwealth Equity Services LLC’s holdings in IDEXX Laboratories were worth $6,811,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of IDXX. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter worth $25,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $31,000. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $38,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.1 %

IDXX opened at $420.99 on Friday. The company has a market capitalization of $34.24 billion, a PE ratio of 39.46, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The business has a 50-day moving average of $437.36 and a 200-day moving average of $445.11. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IDXX. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, March 15th. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Finally, Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.